Document:

EX-10.6

 Exhibit 10.6 

PRIVATE PLACEMENT WARRANTS SUBSCRIPTION AGREEMENT 

THIS PRIVATE PLACEMENT WARRANTS SUBSCRIPTION AGREEMENT, dated as of October 26, 2021 (as it may from time to time be amended and
including all exhibits referenced herein, this “Agreement”), is entered into by and between OPY Acquisition Corp. I, a Delaware corporation (the “Company”) and OPY Acquisition LLC I, a Delaware limited liability
company (the “Purchaser”). 
 WHEREAS, the Company intends to consummate an initial public offering of the Company’s
units (the “Public Offering”), each comprised of one share of the Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), one-half (1/2) of one
redeemable warrant. Each whole warrant entitles the holder to purchase one share of Common Stock at a price of $11.50 per whole share (subject to adjustment). The Purchaser has agreed to purchase an aggregate of 2,100,667 warrants (2,210,667warrants
if the over-allotment option in connection with the Public Offering is exercised in full) (the “Private Placement Warrants”), each Private Placement Warrant being sold at a price of $1.50 per warrant (subject to adjustment).

 NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows: 

AGREEMENT 

Section 1. Authorization, Purchase and Sale; Terms of the Private Placement Warrants. 

A. Authorization of the Private Placement Warrants. The Company has duly authorized the issuance and sale of the Private Placement
Warrants to the Purchaser. 
 B. Purchase and Sale of the Private Placement Warrants. On the date of the consummation of the Public
Offering, and concurrently with the consummation thereof, or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “IPO Closing Date”), the Company shall issue and sell to the Purchaser, and
the Purchaser shall purchase from the Company 2,100,667 Private Placement Warrants at a price of $1.50 per warrant for an aggregate purchase price of $3,151,000 (the “Purchase Price”), which shall be paid by wire transfer of
immediately available funds to the Company in accordance with the Company’s wiring instructions at least one business day prior to the IPO Closing Date. On the IPO Closing Date, the Company shall either, at its option, deliver certificates
evidencing the Private Placement Warrants purchased by the Purchaser on such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form. On the date of the consummation of the closing of the
over-allotment option in connection with the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (each such date, an “Over-allotment Closing Date,” and each Over-allotment Closing
Date (if any) and the IPO Closing Date being sometimes referred to herein as a “Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, up to an aggregate of 110,000 Private
Placement Warrants, in the same proportion as the amount of the over-allotment option that is exercised, at a price of $1.50 per warrant for an aggregate purchase price of up to $150,000 (if the over-allotment option in connection with the Public
Offering is exercised in full) (the “Over-allotment Purchase Price”), which shall be paid by wire transfer of immediately available funds to the Company in accordance with the Company’s wiring instructions at least one business
day prior to such Over-allotment Closing Date. On the Over-allotment Closing Date, upon the payment by the Purchaser of the Over-allotment Purchase Price payable by it by wire transfer of immediately available funds to the Company, the Company shall
either, at its option, deliver certificates evidencing the Private Placement Warrants purchased by the Purchaser on such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form. 

C. Terms of the Private Placement Warrants. 

(i) The Private Placement Warrants shall have their terms set forth in a warrant agreement to be entered into by the Company and a warrant
agent, in connection with the Public Offering (the “Warrant Agreement”). 
 (ii) At or prior to the time of the Closing
Date, the Company and the Purchaser shall enter into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company will grant 

certain registration rights to the Purchaser relating to the Private Placement Warrants and the Shares underlying the Private Placement Warrants. 

 Section 2. Representations and Warranties of the Company. As
a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants, the Company hereby represents and warrants to the Purchaser (which representations and warranties shall survive the Closing Date) that:

 A. Organization and Corporate Power. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the
Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement. 

B. Authorization; No Breach. 

(i) The execution, delivery and performance of this Agreement and the Private Placement Warrants have been duly authorized and approved by the
Company as of the Closing Date. This Agreement constitutes a valid and binding obligation of the Company, enforceable in accordance with its terms. Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and
this Agreement, the Private Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with their terms. 

(ii) The execution and delivery by the Company of this Agreement and the Private Placement Warrants, the issuance and sale of the Private
Placement Warrants, the issuance of the Shares upon exercise of the Private Placement Warrants and the fulfillment of, and compliance with, the respective terms hereof and thereof by the Company, do not and will not as of the Closing Date
(a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s capital stock
or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption, action, notice, declaration or filing, in each case, by or to any court or administrative or governmental body or agency
pursuant to the certificate of incorporation or the bylaws of the Company (in effect on the date hereof or as may be amended prior to completion of the contemplated Public Offering), or any material law, statute, rule or regulation to which the
Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof under federal or state securities laws. 

C. Title to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the
Placement Warrants will be duly and validly issued and the Shares issuable upon exercise of the Private Placement Warrants will be duly and validly issued, fully paid and non-assessable. On the date of
issuance of the Placement Warrants, the Shares issuable upon exercise of the Private Placement Warrants shall have been reserved for issuance. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the
Purchaser will have good title to the Private Placement Warrants and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions
hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser. 

D. Valid Issuance. The total number of shares of all classes of capital stock which the Company has authority to issue is 111,000,000
shares of stock (which consists of 100,000,000 shares of Class A Common Stock, 10,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”). As of the date hereof, the
Company has issued and outstanding 2,875,000 shares of Common Stock (of which up to 375,000 shares are subject to forfeiture as described in the Prospectus (File No. 333-260171) filed pursuant to Rule
424(b)(4) by the Company in connection with the Public Offering) and no shares of Preferred Stock. All of the issued shares of capital stock of the Company have been duly authorized, validly issued, and are fully paid and non-assessable. 

  
 2 

 E. Governmental Consents. No permit, consent, approval or authorization of, or
declaration to or filing with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other transactions contemplated hereby. 

Section 3. Representations and Warranties of the Purchaser. As a material inducement to the Company to enter
into this Agreement and issue and sell the Private Placement Warrants to the Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive the Closing Date) that: 

A. Organization and Requisite Authority. The Purchaser possesses all requisite power and authority necessary to carry out the
transactions contemplated by this Agreement. 
 B. Authorization; No Breach. 

(i) This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or
law). 
 (ii) The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by
the Purchaser does not and shall not as of the Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject that
would materially impact its ability to perform its obligations hereunder. 
 C. Investment Representations. 

(i) The Purchaser is acquiring the Private Placement Warrants and, upon exercise of the Private Placement Warrants, the Shares issuable upon
such exercise (collectively, the “Securities”), for the Purchaser’s own account, for investment purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof. 

(ii) The Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of
1933, as amended (the “Securities Act”). 
 (iii) The Purchaser understands that the Securities are being offered and will
be sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the
representations and warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities. 

(iv) The Purchaser did not enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule
502(c) under the Securities Act. 
 (v) The Purchaser has been furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors of the Company. The
Purchaser understands that its investment in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition
of the Securities. 
 (vi) The Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the
Securities.

  
 3 

 (vii) The Purchaser understands that: (a) the Securities have not been and are not
being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; and
(b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the
terms and conditions of any exemption thereunder. While such Purchaser understands that Rule 144 under the Securities Act is not available for the resale of securities initially issued by shell companies (other than business combination related
shell companies) or issuers that have been at any time previously a shell company, such Purchaser understands that Rule 144 includes an exception to this prohibition if the following conditions are met: (i) the issuer of the securities that was
formerly a shell company has ceased to be a shell company; (ii) the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”); (iii) the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and
materials), other than Form 8-K reports; and (iv) at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is
not a shell company. 
 (viii) The Purchaser understands the high degree of risk associated with investments in the securities of companies
in the development stage such as the Company, has such knowledge and experience in financial and business matters to be able to evaluate the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment
in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies and will have no current or anticipated future needs for
liquidity which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investment in the Securities. 

Section 4. Conditions of the Purchaser’s Obligations. The obligations of the Purchaser to purchase and pay
for the Private Placement Warrants are subject to the fulfillment, on or before the Closing Date, of each of the following conditions: 
 A.
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of the Closing Date as though then made. 

B. Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before the Closing Date. 
 C. No Injunction. No litigation,
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 

D. Warrant Agreement and Registration Rights Agreement. The Company shall have entered into the Warrant Agreement and the Registration
Rights Agreement, each on terms satisfactory to the Purchaser. 
 E. Corporate Consents. The Company shall have obtained the consent
of its Board of Directors authorizing the execution, delivery and performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder. 

Section 5. Conditions of the Company’s Obligations. The obligations of the Company to the Purchaser under
this Agreement are subject to the fulfillment, on or before the Closing Date, of each of the following conditions: 
 A. Representations
and Warranties. The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of the Closing Date as though then made. 

  
 4 

 B. Performance. The Purchaser shall have performed and complied with all agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before the Closing Date. 

C. Corporate Consents. The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and
performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder. 
 D. No
Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any
self-regulatory organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 

E. Warrant Agreement. The Company shall have entered into the Warrant Agreement on terms satisfactory to the Company. 

Section 6. Termination. This Agreement may be terminated at any time after November 30, 2021 upon the
election by either the Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not occur prior to such date. 

Section 7. Survival of Representations and Warranties. All of the representations and warranties contained
herein shall survive the Closing Date. 
 Section 8. Definitions. Terms used but not otherwise defined in
this Agreement shall have the meaning assigned to such terms in the registration statement on Form S-1 that the Company has filed with the Securities and Exchange Commission under the Securities Act in
connection with the Public Offering. 
 Section 9. Miscellaneous. 

A. Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or
on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign
this Agreement without the prior written consent of the other party hereto, other than assignments by the Purchaser to affiliates thereof (including, without limitation, one or more of its members). 

B. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of
this Agreement. 
 C. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, none of which
needs to contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by
e-mail delivery of a “pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and
effect as if such facsimile or “.pdf” signature page were an original thereof. 
 D. Descriptive Headings;
Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of example
rather than by limitation. 
 E. Governing Law. This Agreement shall be deemed to be a contract made under the laws of the State
of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York without regard to the conflicts of laws principles thereof. 

  
 5 

 F. Amendments. This Agreement may not be amended, modified or waived as to any
particular provision, except by a written instrument executed by all parties hereto. 
 [Signature Page Follows]

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective
as of the date first set forth above. 
  

			
	COMPANY:
	
	OPY ACQUISITION CORP. I
		
	By:	 	 /s/ Jonathan Siegel

	Name:	 	Jonathan Siegel
	Title:	 	Chief Executive Officer
	
	PURCHASER:
	
	 OPY ACQUISITION LLC I
 by
its manager, Oppenheimer Alternative Investment Management, LLC

		
	By:	 	 /s/ Robert S. Lowenthal

	Name:	 	Robert S. Lowenthal
	Title:	 	Senior Vice President

 [Signature Page to Private Placement Warrants Subscription Agreement] 

  
 7Exhibit 4.17

 

THE SECURITIES REPRESENTED BY THIS DOCUMENT
AND THE SHARES ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF BY
THE HOLDER EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OR AN EXEMPTION THEREFROM AS CONFIRMED
BY AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT. 

 

REVOLVING CONVERTIBLE PROMISSORY NOTE 

 

	Up to $2,500,000	June 30, 2021

 

 

FOR VALUE RECEIVED,
the undersigned FREECAST, INC., a Florida corporation (“Maker”) hereby promises to pay to the order of NEXTELLIGENCE,
INC. (“Payee”) at such place as Payee may designate from time to time in writing to Maker, in immediately available
funds of official currency of the United States, the aggregate principal amount as may be outstanding hereunder from time to time not
to exceed Two Million Five Hundred Thousand Dollars ($2,500,000), together with interest thereon from the date of this Convertible Promissory
Note (this “Note”), as provided herein.

 

By acceptance of this Note,
Payee agrees that it will promptly deliver and surrender this Note to Maker upon full payment thereof.

 

1. Principal
Balance. This Note evidences a loan up to the maximum principal sum specified above, less the aggregate amount of all principal
repayments made under this Note by Maker to Payee.

 

2. Interest
Rate. Interest shall accrue on the aggregate unpaid principal balance outstanding hereunder from time to time at the rate of 12%
per annum from but excluding the date first set forth above to and including the Maturity Date (as defined below). Interest shall accrue
on any principal balance that is not paid on the earlier of the Maturity Date and the date of an Event of Default (as defined below) at
the rate of 18% per annum from and including the Maturity Date or the date of such Event of Default to but excluding the date of payment.
In no event, however, shall interest be payable at a rate higher than the highest rate permitted by applicable law. Interest on the principal
balance outstanding will be calculated on the basis of the actual number of days elapsed over an assumed year consisting of 365 days,
to the date of receipt by Payee of any interest and/or principal. Interest shall be payable on the unpaid principal balance of this Note,
as the same may exist from time to time, from the date of issuance until paid or converted in full, in accordance with the terms herein
and shall be payable: (a) on the Maturity Date; and (b) on any earlier date of payment or conversion of principal, in whole or in part
and, if in part, as to the portion paid or converted.

 

3. Payment
Terms. Any outstanding principal balance and accrued unpaid interest shall be paid to Payee in full no later than June 30, 2024
(the “Maturity Date”).

 

4. Conversion
Rights.

 

(a) Payee
shall have the right by notice to Maker (“Conversion Notice”) to elect to convert the principal amount of this Note and
accrued and unpaid interest thereon (the “Convertible Amount”) in whole or in part into shares (“Shares”)
of Maker’s common stock, par value of $0.0001 per share (“Common Stock”), at the Conversion Price (as defined below)
in lieu of having Maker repay this Note pursuant to Section 3 above. The date notice of conversion of all or any portion of the Note is
given by Payee to Maker is referred to as the “Conversion Date.” No fractional Shares will be issued in connection with
any conversion of the Convertible Amount, but instead will be rounded up to the nearest whole Share.

 

     

     

    

 

(b) The
Convertible Amount is convertible at any time at the option of Payee by notice to Maker into that number of Shares equal to the Convertible
Amount divided by Twenty-Five Cents ($0.25), subject to adjustment as provided in the remaining provisions of this Note (the “Conversion
Price”). The Shares or other securities into which this Note is convertible (and any Shares issued upon conversion or exercise
of any such other securities) are referred to as the “Conversion Securities.” Payee may elect to convert this Note in
part under any provision hereof permitting conversion and may elect multiple conversions.

 

(c) Upon
conversion of any portion of this Note and delivery of the Conversion Securities in accordance with the terms hereof, the portion of the
principal balance of this Note so converted and all accrued interest due thereon as of the date of conversion will be deemed paid in full,
and upon conversion of all outstanding principal and interest the Note will be deemed cancelled and of no force or effect.

 

5. Additional
Matters Relating to Conversion.

 

(a) If
Maker shall effect a stock split of the outstanding Common Stock, the applicable Conversion Price in effect immediately prior to the stock
split shall be proportionately decreased. If Maker shall combine the outstanding shares of Common Stock, the applicable Conversion Price
in effect immediately prior to the combination shall be proportionately increased.

 

 

(b) Maker
shall at all times when this Note shall be outstanding, reserve and keep available out of Maker’s authorized but unissued Common Stock
the total number of Shares for which this Note and all interest accrued thereon are at any time convertible.

 

6. Prepayment.
Notwithstanding anything contained herein to the contrary, this Note is subject to prepayment in whole or in part at any time at the sole
and absolute option of Maker, upon five business days’ prior written notice to Payee. The conversion rights of Payee shall continue to
be exercisable during such five day period and thereafter until payment is made in full to Payee, and Maker shall duly honor all conversions
as to which a Conversion Notice is given by Payee during such five day period.

 

7. Events
of Default. Any of the following shall constitute an “Event of Default” under this Note, and shall give rise to the
remedies provided in Section 8 herein.

 

(a) Maker
defaults in the payment of principal of or interest on this Note when due, including upon any prepayment provided for herein.

 

(b) Maker
fails to or is unable to (including by reason of Maker having insufficient authorized capital), or notifies Payee, at any time, that it
does not intend to comply with proper requests for conversion of the Note.

 

(c) Maker
fails to instruct its transfer agent to remove any legends from Conversion Securities eligible to be sold under Rule 144 of the Securities
Act and issue such unlegended certificates to Payee (or Payee’s transferee, if such request is made in connection with a transfer of Conversion
Securities), or to cause to be provided to such transfer agent any opinion of counsel and/or certification of Maker required in order
for such transfer agent to comply with such instructions, within three business days of Payee’s request so long as Payee has provided
a customary representation letter to Maker that provides a reasonable basis to conclude, to the extent such conclusion is dependent upon
matters to be confirmed by Payee, that such shares of Common Stock can be sold pursuant to Rule 144.

 

    2

     

    

 

(d) Maker
defaults in the compliance with any other term contained in this Note (which default is not described in subsections (a) through (c) above)
and such default is not remedied or waived within ten business days after receipt by Maker of notice from Payee of such default.

 

(e)  Maker
shall be subject to a Bankruptcy Event. For purposes hereof, “Bankruptcy Event” means any of the following events: (i)
Maker commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction relating to Maker or any Significant Subsidiary thereof; (ii) there is commenced
against Maker any such case or proceeding that is not dismissed within 60 days after commencement; (iii) Maker is adjudicated insolvent
or bankrupt or any order of relief or other order approving any such case or proceeding is entered; (iv) Maker suffers any appointment
of any custodian or the like for it or any substantial part of its property that is not discharged or stayed within 60 calendar days after
such appointment; (v) Maker makes a general assignment for the benefit of creditors; (vi) Maker calls a meeting of its creditors with
a view to arranging a composition, adjustment or restructuring of its debts; or (vii) Maker, by any act or failure to act, expressly indicates
its consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting
any of the foregoing.

 

8. Remedies
on Event of Default. If any Event of Default will occur, Payee shall, in addition to any and all other available rights and remedies,
have the right, at Payee’s option, to: (a) declare the entire unpaid outstanding principal balance of this Note, together with all interest
accrued thereon, and all other sums due by Maker hereunder, to be immediately due and payable without presentment, demand, protest, or
notice, all of which are hereby expressly unconditionally and irrevocably waived by Maker, provided that upon the occurrence of an Event
of Default described in Section 7(e), the entire unpaid outstanding principal balance of this Note, together with all interest accrued
thereon, and all other sums due by Maker hereunder, shall be immediately due and payable without any declaration or other act by Payee;
and (b) pursue any and all available remedies for the collection of such principal and interest and all other sums due by Maker hereunder
and to enforce its rights as described herein; and in such case Payee may also recover all costs of suit and other expenses in connection
therewith, including reasonable attorney’s fees for collection and the right to equitable relief to enforce Payee’s rights as set forth
herein without the requirement to post any bond or other financial surety. The remedies provided in this Note may be exercised by Payee
without notice to Maker (to the extent permitted by law and except as notice is herein expressly required), and will be in addition to
and not in substitution for the rights and remedies which would otherwise be vested in Payee for the recovery of damages or otherwise
in the event of a breach of any of the undertakings of Maker hereunder. No failure by Payee to exercise and no delay in exercising any
right, power or privilege under this Note will operate as a waiver thereof, nor will any single or partial exercise of any right, power
or privilege hereunder preclude any other, further or additional exercise thereof.

 

9. Governing
Law; Venue; Waiver of Jury Trial. This Note shall be governed by and construed in accordance with the laws of the State of Florida
applied to contracts to be performed wholly within the State of Florida, without regard to conflicts of laws principles. Any judicial
proceeding brought against Maker with respect to this Note or any related agreement may be brought in any court located in the State of
Florida, United States of America, and, by execution and delivery of this Note, Maker accepts for itself and in connection with its properties,
generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts, and irrevocably agrees to be bound by any judgment
rendered thereby in connection with this Note. Maker hereby waives personal service of any and all process upon it and consents that all
such service of process may be made by registered mail (return receipt requested) directed to Maker at its address set forth below and
service so made shall be deemed completed five days after the same shall have been so deposited in the mails of the United States of America.
Nothing herein shall affect the right to serve process in any manner permitted by law or shall limit the right of Payee to bring proceedings
against Maker in the courts of any other jurisdiction. Maker waives any objection to jurisdiction and venue of any action instituted hereunder
and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. Any judicial proceeding by
Maker against Payee involving, directly or indirectly, any matter or claim in any way arising out of, related to or connected with this
Note or any related agreement, shall be brought only in a federal or state court located in the State of Florida.

 

    3

     

    

 

MAKER HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL
BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS NOTE OR ANY OTHER INSTRUMENT, DOCUMENT OR NOTE EXECUTED
OR DELIVERED IN CONNECTION HEREWITH, OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR
ANY OF THEM WITH RESPECT TO THIS NOTE OR ANY OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR
THE TRANSACTIONS RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR
TORT OR OTHERWISE AND EACH PARTY HEREBY CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL
WITHOUT A JURY, AND THAT ANY PARTY TO THIS NOTE MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE
OF THE CONSENTS OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

10. Amendment.
Neither any provision of this Note nor any performance hereunder may be amended or waived orally, but only by an agreement in writing
and signed by the party against whom enforcement of any waiver, change, modification or discharge is sought.

 

11. Binding
Effect. The rights and obligations of Maker under this Note will be binding upon its successors, assigns, heirs, administrators
and transferees.

 

12. Successors
and Assigns. This Note may be assigned, transferred or negotiated by Payee to any person at any time (a “Transfer”)
only upon its surrender to Maker for registration of Transfer, duly endorsed, or accompanied by a duly executed written instrument of
Transfer in form satisfactory to Maker. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a
new note for like principal amount and interest shall be issued to, and registered in the name of, the transferee. Interest and principal
shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of Maker’s obligation to pay
such interest and principal. Maker may not assign or transfer this Note or any of its rights hereunder without the prior written consent
of Payee. This Note shall inure to the benefit of and be binding upon the parties hereto and their permitted assigns.

 

EXECUTED as of the
date first set forth above.

 

	FREECAST, INC. 	 
	 	 	 
	BY:	/s/ William A.
    Mobley, Jr.	 
	 	William A. Mobley, Jr., CEO	 

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]